On May 13, 2022, the FDA approved Eli Lilly’s Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes. Mounjaro™ is administered once every week as an injection under the skin. Mounjaro™ is a novel dual-targeting medication that activates glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. GLP-1 and GIP are both hormones that are involved in blood sugar control. GLP-1 receptor agonists (GLP-1 RA) have been on the market for years and have been proven to help patients control their blood sugar and reduce the risk of cardiovascular disease. Mounjaro is the first diabetes agent approved for use by the FDA that works by acting on the GIP receptors. The approval was granted after results from five clinical trials showed safety and efficacy of Mounjaro™ when compared against, or in combination with, placebo and other diabetes medications. Patients who received the maximum recommended weekly dose of Mounjaro™ (15 milligrams) had significantly lower hemoglobin A1c (HbA1c) levels when compared to placebo (1.6% lower), long-acting insulins degludec (Tresiba®) and glargine (Lantus®) (0.9%-1.0% lower), and the GLP-1 RA semaglutide (Ozempic®) (0.5% lower). Mounjaro™ was also shown to have a significant impact on weight loss, with participants who received the maximum dose having an average weight loss of 15 pounds more than those who received placebo. In patients who received insulin in combination with placebo or Mounjaro™, the average weight loss was 23 pounds higher in the Mounjaro™ treatment group. Patients who received the maximum dose of Mounjaro™ experienced an average weight loss 12 pounds greater than those who received semaglutide, a GLP-1 RA which carries an FDA approved indication for weight loss. Of note, patients who received insulin without Mounjaro™ ended up gaining weight during the study. Side effects of Mounjaro™ are similar to those seen with traditional GLP-1 RA’s (Ozempic®, Trulicity, etc.) on the market, and include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort and abdominal pain. Mounjaro™ should not be used in patients with a personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, or type 1 diabetes. Mounjaro™ has not been studied in patients with a history of pancreas inflammation (pancreatitis).